MitoQ reduces senescence burden in doxorubicin-treated endothelial cells by reducing mitochondrial ROS and DNA damage
Year: 2025
Type: article
Abstract: Doxorubicin (DOXO) is a widely used chemotherapy drug that can damage blood vessels and promote cardiovascular disease. This study shows that MitoQ, a mitochondria-targeted antioxidant, protects endothelial cells from DOXO-induced oxidative stress, DNA damage, and senescence. By preserving mitochondrial health, MitoQ may prevent vascular toxicity in cancer patients receiving DOXO, offering a potential strategy to improve cardiovascular outcomes in survivorship.
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: G150763035, Investigating novel intra- and extra-cellular regulators of telomere-mediated proliferative boundaries, G1952563938, G2067428092, G2615437256, G3338008254, G5447085330, G5562177406, Improving healthspan through discovery of potent NAMPT activators from a DNA-encoded library, G9000051283, G9000153163, G9000257828, G9000261771, G9000341470, Integrative Mechanisms of Vascular Aging, Tissue senescence and age-associated metabolic dysfunction: the role of immune cell mediated inflammation
OpenAlex ID: W4414645218
